This bill updates the "competitive need limitation" for duty-free imports from beneficiary developing countries under the Trade Act of 1974. It increases the annual cap for eligible imports from $75 million to $600 million and changes how the limit is calculated to count only duty-free entries during a calendar year. The President must restore duty-free treatment for most eligible articles within 120 days of the bill's enactment, with a one-year review period for sensitive products requiring continued withholding. The bill also requires a report to Congress within one year detailing restored and withheld duty-free treatments. This directly affects importers of goods from designated developing countries eligible for trade benefits.
HR 6344, the Simon Crosier Act, requires Medicare and Medicaid providers to establish written policies for do-not-resuscitate (DNR) orders involving unemancipated minors (under 18 without legal independence). It mandates that providers must inform at least one parent or legal guardian in person or by phone (with 72 hours of effort) before considering a DNR, allow parents/guardians to refuse consent, and prohibit overriding parental objections to life-sustaining treatment. The bill also requires providers to continue life-sustaining care for 15 days if a parent requests a transfer and explicitly prohibits using disability as the sole basis for DNR decisions. These requirements apply to all Medicare/Medicaid-covered facilities and directly affect minors, their parents, and healthcare providers.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
This bill revokes a specific waiver determination related to Iran sanctions that the State Department submitted to Congress on September 11, 2023. It directly affects the application of certain sanctions under two 2012 laws: the National Defense Authorization Act (Section 1245(d)(5)) and the Iran Freedom and Counter-Proliferation Act (Sections 1244(i) and 1247(f)). The bill’s key provision is to nullify the September 11 waiver, meaning the underlying sanctions must now be enforced without exception. This is a procedural change that reinstates the original sanctions requirements, not a new policy.
This bill amends the tax code to allow individuals to treat medical expenses paid before opening a Health Savings Account (HSA) as qualified expenses, if the HSA is established within 60 days of starting a high-deductible health plan. It directly affects people who set up an HSA shortly after enrolling in a qualifying health plan, making it easier to use HSA funds for prior medical costs. The key provision treats the HSA as if it existed from the start date of their health coverage for expense eligibility purposes. The change applies to health coverage beginning after December 31, 2023. This is a technical adjustment to HSA rules, not a broad policy change.
The DRA of 2023 adjusts Medicare payment rates for specific durable medical equipment (DME) items that were part of the 2021 competitive bidding program but for which no supplier contracts were finalized. It directly affects DME suppliers and Medicare beneficiaries by establishing a new 2024 payment formula: 90% of the adjusted payment amount plus 10% of the unadjusted fee schedule for eligible items. The bill also extends a temporary transition rule for non-rural areas through December 31, 2024, while delaying a regulatory change until 2025. These provisions aim to stabilize payments for DME items that did not transition to standard pricing under prior rules.
The Maintaining Investments in New Innovation Act (HR 5547) extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines an "advanced drug product" as a drug using genetically targeted technology to change how genes work, such as drugs that suppress or activate gene function. The bill amends the Social Security Act to update the definition of "qualifying single source drug" to include these advanced therapies with the longer exclusivity period. This change directly affects drug manufacturers developing such advanced therapies and influences Medicare's drug coverage rules by delaying generic competition for these specific treatments.
This bill changes Medicare payment rules for anesthesiologist services in specific rural hospitals. It requires Medicare to pay for anesthesiologist services in qualifying rural hospitals using the same "reasonable cost, pass-through" reimbursement method currently used for certified registered nurse anesthetists (CRNAs), rather than the standard physician payment rate. The bill directly affects rural hospitals and anesthesiologists working in those facilities, ensuring they receive comparable reimbursement to CRNAs under existing rules. The change applies to services provided during cost reporting periods starting after the bill's enactment date. This is a technical adjustment to payment methodology, not a new coverage benefit.
HR 5208, the Health Care Provider Shortage Minimization Act of 2023, clarifies tax treatment for temporary healthcare workers. It amends the tax code to specify that locum tenens physicians and advanced care practitioners (like nurse practitioners or physician assistants) providing services for up to one year at a single site are not treated as employees for tax purposes. This means the workers themselves, the healthcare facilities hiring them, and payors avoid employer tax obligations related to these temporary services. The bill directly affects temporary healthcare providers and facilities seeking to fill staffing gaps without complex employment tax compliance.
The Preserving Access to Home Health Act of 2023 repeals a 2018 payment adjustment for Medicare home health agencies, restoring prior payment rates for 2024 and subsequent years. It requires the Medicare Payment Advisory Commission (MedPAC) to analyze how home health agencies' financial performance affects access to care, including reviewing spending and utilization data across Medicare, Medicaid, and other payers. Starting in 2025, the bill mandates home health agencies to report detailed data on visit volumes and payments by payer source (Medicare, Medicaid, private insurers) through updated cost reports. This data will help MedPAC assess payment policy impacts on access to home health services for Medicare beneficiaries.
HR 4794, the Dietary Supplements Access Act, allows health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs) to cover dietary supplements as qualified medical expenses. The bill amends the Internal Revenue Code to treat payments for dietary supplements - defined under federal law (21 U.S.C. 321(ff)) - as medical care, directly affecting individuals using these accounts to pay for supplements like vitamins or minerals. Key provisions require HSAs, FSAs, and HRAs to reimburse supplement costs under the same rules as other medical expenses. The change applies to taxable years beginning after the bill’s enactment.
This bill expands Medicare coverage to include home infusion treatment for people with Alpha-1 Antitrypsin Deficiency Disorder, a genetic condition causing lung and liver damage. It specifically covers "augmentation therapy" (a standard treatment using Alpha-1 Proteinase Inhibitor) when administered in a patient's home by qualified providers. Medicare will pay 80% of the cost for intravenous kits and up to 2 hours of nursing care during these home infusions, starting January 1, 2025. The change directly affects Medicare beneficiaries with this condition who require home-based treatment and their qualified home infusion providers.
